Form 4: Unicycive Therapeutics Executive Acquires Stock Options
SEC Form 4
Pramod Gupta, EVP at Unicycive Therapeutics, reports acquisition of stock options.
Summary
- On April 15, 2024, Pramod Gupta, EVP of Pharmaceuticals and Business Development at Unicycive Therapeutics, acquired 463,250 stock options at a price of $1.14.
- These options are exercisable for common stock.
- Following the transaction, Gupta directly owns 2,038,112 derivative securities.
- 115,813 of the stock options vest on the first anniversary of the date of grant, with the remaining options vesting monthly thereafter.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock option acquisition, neither particularly positive nor negative.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the holdings of company insiders.
Stakeholder Impact
- The acquisition of stock options by an executive could be viewed positively by shareholders as it aligns the executive's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 04/15/2024 | Date of transaction: Pramod Gupta acquired stock options. |
| 04/15/2024 | Date of grant of stock options. |
| 04/15/2034 | Expiration date of stock options. |
| 04/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.